IDEXX Laboratories, Inc. (IDXX) Earnings Call Transcripts

IDEXX Laboratories, Inc.'s Latest Earnings Call - September 14, 2026

In the Q2 2026 earnings call for IDEXX Laboratories, management reaffirmed strong momentum in the business, highlighting double-digit growth in recurring revenues from both reference labs and VetLab. The company raised its guidance for the year, reflecting confidence in its innovation-driven growth strategy, with a focus on diagnostics that are underpenetrated globally. Key metrics showed robust customer growth and improved operating margins, with management emphasizing the long-term potential of the diagnostics market, projected to reach a $45 billion total addressable market (TAM).

Reported metrics

Guidance from management

Management maintained its guidance for 2026, projecting a decline in vet office visits of 1.5% to 2%. They expressed confidence in long-term growth driven by innovation but did not provide specific guidance for 2027.

What management said

Yes. If you look at what we did on the Catalyst, and Erin, you know this over a decade, we expanded the economic value of the catalyst in our customers' hands and for us by 2.5-fold. And that was a combination of menu innovation, supporting utilization, all of these things. That's exactly the type of thing that we see in the future for inVue Dx as well.

Yes. Just echoing what Mike highlighted, we have an ongoing active process where we're always looking outside our 4 walls for assets that really fit our themes and our principles as a company. And when we find those, we're willing to make that type of investment. But it really starts with our organic growth strategy. Those will be to help augment and continue to strengthen kind of our asset base overall. And then exc...

What analysts pressed on

Analysts expressed concerns about the sustainability of vet office visit trends, questioning whether the current decline is structural or temporary. There were also inquiries about the potential impact of economic pressures on pet care spending.

Main topics on the call

• Revenue Growth Acceleration — IDEXX reported double-digit growth in recurring revenue streams, particularly in reference labs and VetLab. CEO Mike Erickson stated, "we're seeing that flow through into double-digit growth, both in reference labs recur...
• Innovation-Driven Strategy — Management emphasized the importance of innovation in driving growth, noting that customers adopting IDEXX innovations grow faster. Erickson mentioned, "customers that adopt our IDEXX innovations grow faster," indicating...
• Veterinary Visit Trends — Management acknowledged a headwind in vet office visit growth, projecting a decline of 1.5% to 2% for the year. However, they noted that diagnostic frequency and utilization are improving, with a 50 basis point annual in...
• Cancer Diagnostics Expansion — The rollout of Cancer Dx is expected to drive market share gains, with 20% of its customers not using IDEXX as their primary reference lab. Erickson stated, "Cancer Dx is a total breakthrough from a testing platform stan...

Read the full IDEXX Laboratories, Inc. transcript (September 14, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 64 IDEXX Laboratories, Inc. earnings call transcripts on record, spanning January 31, 2020 to September 14, 2026. Based on this history, IDEXX Laboratories, Inc. reports quarterly. The most recent call on file is dated September 14, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

IDXX

Exchange

NasdaqGS

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

64

First call

January 31, 2020

Most recent

September 14, 2026

Reporting cadence

quarterly